Wuhan Mingde Biological Technology Co., Ltd. plans to acquire 100% equity of Wuhan Bicare Rescue Products Co., Ltd. from Blue Sail Medical Co., Ltd. for a total cash consideration of 190 million RMB. This transaction constitutes a major asset purchase aimed at expanding the company's business scope. The report outlines the transaction structure, key definitions, and regulatory compliance requirements for the acquisition.
Summary generated by AI · Always verify with source document
Stock Code: 002932 Stock Abbreviation: *ST Mingde Listing Venue: Shenzhen Stock Exchange
Wuhan Mingde Biological Technology Co., Ltd.
Major Asset Purchase Report (Draft) Summary
(Revised)
| Project | Name of Counterparty |
|---|---|
| Counterparty for Asset Purchase | Blue Sail Medical Co., Ltd. |
Independent Financial Advisor
July 2026
Definitions
Unless the context otherwise requires, the following abbreviations have the following meanings in this report summary:
I. General Terms
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.